Key result
Implantable cardioverter-defibrillators and cardiac resynchronization therapy are critical components of current heart failure therapy that significantly lower mortality and morbidity, though they remain underutilized.
Why the study?
Heart failure mortality remains high, not all patients benefit equally from ICDs, and evidence-based devices like CRT continue to be underutilized.
Do implantable cardioverter-defibrillators and cardiac resynchronization therapy reduce mortality and sudden cardiac death in patients with heart failure?
Do implantable cardioverter-defibrillators and cardiac resynchronization therapy reduce mortality and sudden cardiac death in patients with heart failure?
This review emphasizes the established mortality benefits of ICDs and CRT in heart failure patients while highlighting their underutilization and the potential of novel technologies like subcutaneous and leadless devices.
Despite constant breakthroughs in heart failure (HF) therapy, the population of HF patients resume to grow and is linked to increased mortality and morbidity. Ventricular arrhythmias (VA) are one of the leading causes of mortality in HF subjects. Implantable cardioverter-defibrillators (ICDs) are currently the gold standard in treatment, preventing arrhythmic sudden cardiac death (SCD) episodes. However, the death rates related to HF remain elevated, as not all HF subjects benefit equally. Cardiac resynchronization therapy (CRT) has emerged as a novel approach for HF patients. These devices have been thoroughly investigated in major randomized controlled studies but continue to be underutilized in various countries. This review discusses the use of ICD in HF populations on top of treatments.
No takes yet. Share an insight, caveat, or question.
Spartalis et al. (2021) conducted a review in Heart failure. Implantable cardioverter-defibrillators (ICDs) and Cardiac resynchronization therapy (CRT) was evaluated. Implantable cardioverter-defibrillators and cardiac resynchronization therapy are critical components of current heart failure therapy that significantly lower mortality and morbidity, though they remain underutilized.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: